References
- Nature – Challenges in Irreproducible Research . www.nature.com/nature/focus/reproducibility.
- Prinz F , SchlangeT, AsadullahK. Believe it or not: how much can we rely on published data on potential drug targets?Nat. Rev. Drug Discov.10, 712 (2011).
- Begley CG , EllisLM. Drug development: raise standards for preclinical cancer research. Nature483, 531–533 (2012).
- Tufts Center for the Study of Drug Development – Cost to Develop and Win Marketing Approval for a New Drug Is $2.6 Billion. http://csdd.tufts.edu/news/complete_story/pr_tufts_csdd_ 2014_cost_study.
- Scannell JW , BlanckleyA, BoldonHet al. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov.11, 191–200 (2012).
- Khanna I . Drug discovery in pharmaceutical industry: productivity challenges and trends. Drug Discov. Today17, 1088–1102 (2012).
- Collisson EA et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature511, 543–550 (2014).
- Gerlinger M et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med.366, 883–892 (2012).
- Wang Y et al. Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature512, 155–160 (2014).
- Aviesan–Sanofi partnership. www.aviesan.fr/en.
- Cancer Research Technology Cancer Alliances. www.crtdiscoverylabs.com.
- Cancer Research UK Drug Discovery Project Grants. www.cancerresearchuk.org/funding-for-researchers.
- California Institute for Biomedical Research. http://calibr.org/about.
- Cancer Target Discovery and Development CTD2. www.ocg.cancer.gov/programs/ctd2.
- Centers for Therapeutic Innovation. www.pfizercti.com.
- CoLaborator. www.colaborator.bayer.com/en/index.php.
- European Lead Factory. www.europeanleadfactory.eu.
- J&J Innovation Centre. www.jnjinnovation.com.
- Open Innovation. openinnovation.astrazeneca.com.
- Open Innovation Drug Discovery. https://openinnovation.lilly.com/dd.
- Quest for cures. www.lls.org/research/quest-for-cures.
- Structural Genomics Consortium. www.thesgc.org.
- Target Validation Centre. www.targetvalidation.org.
- Tri-Institutional Therapeutics Discovery Network. www.triitdi.org.
- Stock JK , JonesNP, HammondsT, RoffeyJ, DillonC. Addressing the right targets in oncology: challenges and alternative approaches. J. Biomol. Screen.20 (3), 305–317 (2015).
- Cancer Research Technology – CRT and AstraZeneca form major alliance to create ‘cancer metabolism’ drugs. www.cancertechnology.com/crt-and-astrazeneca-form-major-alliance-create-cancer-metabolism-drugs.
- Cancer Research Technology – FORMA Therapeutics and CRT to discover cancer drugs targeting deubiquitinating enzymes (DUBs). www.cancertechnology.com/forma-therapeutics-and-crt-discover-cancer-drugs-targeting-deubiquitinating-enzymes-dubs.
- Cancer Research Technology – CRT and Teva Pharmaceuticals Form R&D Alliance for Cancer DNA Damage Response Drugs. www.cancertechnology.com/crt-and-teva-pharmaceuticals-form-rd-alliance-cancer-dna-damage-response-drugs.